Session Details

Fibrinogen Factor XIII and Thrombin 2

Tuesday, 23 March 2004 14:00 -15:30

Co-Chair Dr Robert AS Ariens Academic Unit of Molecular Vascular Medicine, University of LeedsUnited Kingdom
Co-Chair Nuala A Booth University of AberdeenUnited Kingdom

A Randomized, Placebo-Controlled, Double-Blind, Multi-dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers
  • Thomas C Reynolds, ZymoGenetics, United States
  • Hyperglycaemia Increases Fibrinopeptide B Cleavage and Alters Fibrin Structure: A Mechanism for Increased Mortality in Subjects with Acute Myocardial Infarction
  • Emma J Dunn, Academic Unit of Molecular Vascular Medicine, University of Leeds, United Kingdom
  • Recombinant RGD-hirudin, A Novel Anticoagulant
  • Professor Hou-yan Song, The Key Laboratory of Molecular Medicine, Ministry of Education, Fudan University, China
  • The Resistance of Model Thrombi to Lysis is Increased by the Activity of Transglutaminases
  • Nuala A Booth, University of Aberdeen, United Kingdom
  • A Simplified Test of Fibrin Generation and Lysis can Identify Patients in Hypercoagulable States
  • Marie-Christine J Morel-Kopp, Northern Blood Research Centre, Australia
  • uPA Deficiency Promotes Muscular Dystrophy in mdx Mice: Inhibitory Role of Fibrin in mdx Muscle Regeneration
  • Pura Munoz-Canoves, Center for Genomic Regulation, Spain